Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Antidepressant Safety Concerns Not Impacting Forest's SSRI Sales

This article was originally published in The Pink Sheet Daily

Executive Summary

Publicity surrounding the safety of antidepressants in adult and pediatric patients is not having an impact on Forest's sales of Lexapro and Celexa, President Kenneth Goodman said during a July 20 conference call

You may also be interested in...

Organon Submitting Remeron Pediatric Data To Congress

Organon is preparing its response to congressional investigators looking into the handling of pediatric research for antidepressants, the company said during a July 19 conference call

House Subcommittee Postpones Pediatric Antidepressant Hearing

A conflict caused the Energy & Commerce/Oversight Subcommittee to postpone a July 20 hearing on clinical trial publication and disclosure issues. Results from a new study evaluating suicidal behavior in patients taking SSRIs versus tricyclic antidepressants could be a topic of discussion during the rescheduled hearing.

GSK Handling Of Paxil Data On Pediatric Use Is Subject Of N.Y. Lawsuit

The state attorney general alleges that GSK failed to publish information about the safety and efficacy of Paxil in children. The lawsuit seeks disgorgement of profits. GSK maintains that it has publicly communicated the data from its pediatric studies.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts